Compare Stocks: IVF, BMGL, AIDX, and GXAI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.47	$0.52	$0.40 ▼ $50.00	$5.94M	N/A	61,151 shs	28,819 shs
BMGL Basel Medical Group	$4.61	$5.35	$3.90 ▼ $23.28	$7.28M	0.26	1.65 million shs	35,592 shs
GXAI Gaxos.ai	$0.60	$0.86	$0.59 ▼ $2.63	$6.45M	0.96	260,846 shs	132,552 shs
IVF INVO Fertility	$0.97	$1.03	$0.90 ▼ $84.40	$2.43M	2.34	341,699 shs	111,554 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	0.00%	-16.95%	-16.09%	-23.98%	+46,509,900.00%
BMGL Basel Medical Group	0.00%	-1.60%	-13.02%	-37.80%	-78.54%
GXAI Gaxos.ai	0.00%	-11.75%	-31.69%	-51.59%	-64.89%
IVF INVO Fertility	0.00%	+0.09%	-8.49%	-30.22%	-97.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIDX 20/20 Biolabs	$0.47	$0.52	$0.40 ▼ $50.00	$5.94M	N/A	61,151 shs	28,819 shs
BMGL Basel Medical Group	$4.61	$5.35	$3.90 ▼ $23.28	$7.28M	0.26	1.65 million shs	35,592 shs
GXAI Gaxos.ai	$0.60	$0.86	$0.59 ▼ $2.63	$6.45M	0.96	260,846 shs	132,552 shs
IVF INVO Fertility	$0.97	$1.03	$0.90 ▼ $84.40	$2.43M	2.34	341,699 shs	111,554 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIDX 20/20 Biolabs	0.00%	-16.95%	-16.09%	-23.98%	+46,509,900.00%
BMGL Basel Medical Group	0.00%	-1.60%	-13.02%	-37.80%	-78.54%
GXAI Gaxos.ai	0.00%	-11.75%	-31.69%	-51.59%	-64.89%
IVF INVO Fertility	0.00%	+0.09%	-8.49%	-30.22%	-97.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIDX 20/20 Biolabs	2.00	Hold	$5.00	975.04% Upside
BMGL Basel Medical Group	1.00	Sell	N/A	N/A
GXAI Gaxos.ai	1.00	Sell	N/A	N/A
IVF INVO Fertility	2.50	Moderate Buy	$20.00	1,961.86% Upside

Current Analyst Ratings Breakdown

Latest IVF, BMGL, AIDX, and GXAI Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	AIDX 20/20 Biolabs	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
8/3/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/3/2026	IVF INVO Fertility	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/31/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	BMGL Basel Medical Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/16/2026	GXAI Gaxos.ai	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIDX 20/20 Biolabs	$2.05M	2.90	N/A	N/A	N/A	∞
BMGL Basel Medical Group	$8.90M	0.82	N/A	N/A	$2.44 per share	1.89
GXAI Gaxos.ai	$6.01M	1.07	N/A	N/A	$1.79 per share	0.34
IVF INVO Fertility	$7.53M	0.32	N/A	N/A	$3.46 per share	0.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIDX 20/20 Biolabs	-$3.74M	-$0.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	-$9.50M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	-$3.90M	-$0.50	N/A	N/A	N/A	-64.81%	-38.79%	-36.99%	11/12/2026 (Estimated)
IVF INVO Fertility	-$25.13M	-$33.83	N/A	N/A	N/A	-116.29%	-85.54%	-31.05%	N/A

Latest IVF, BMGL, AIDX, and GXAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	AIDX 20/20 Biolabs	N/A	-$0.26	N/A	-$0.26	N/A	$0.73 million
8/14/2026	Q2 2026	IVF INVO Fertility	N/A	$0.35	N/A	$0.35	N/A	$2.18 million
8/12/2026	Q2 2026	GXAI Gaxos.ai	-$0.15	$0.02	+$0.17	$0.02	$1.80 million	$2.46 million
6/26/2026	Q2 2026	BMGL Basel Medical Group	N/A	$0.01	N/A	$0.0050	N/A	$3.21 million
6/22/2026	Q1 2026	IVF INVO Fertility	N/A	-$3.38	N/A	-$3.38	N/A	$2.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIDX 20/20 Biolabs	N/A	N/A	N/A	N/A	N/A
BMGL Basel Medical Group	N/A	N/A	N/A	N/A	N/A
GXAI Gaxos.ai	N/A	N/A	N/A	N/A	N/A
IVF INVO Fertility	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIDX 20/20 Biolabs	N/A	1.99	1.95
BMGL Basel Medical Group	0.93	1.88	1.83
GXAI Gaxos.ai	N/A	10.56	10.56
IVF INVO Fertility	0.03	0.71	0.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIDX 20/20 Biolabs	N/A
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	42.62%
IVF INVO Fertility	12.02%

Insider Ownership

Company	Insider Ownership
AIDX 20/20 Biolabs	29.80%
BMGL Basel Medical Group	N/A
GXAI Gaxos.ai	3.17%
IVF INVO Fertility	0.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIDX 20/20 Biolabs	14	12.77 million	8.97 million	N/A
BMGL Basel Medical Group	70	1.58 million	N/A	N/A
GXAI Gaxos.ai	3	10.75 million	10.40 million	N/A
IVF INVO Fertility	46	2.51 million	2.50 million	No Data

IVF, BMGL, AIDX, and GXAI Headlines

Recent News About These Companies

INVO Fertility, Inc (NASDAQ:IVF) Short Interest Up 60.9% in August

September 19 at 4:21 AM | americanbankingnews.com

Head-To-Head Review: Hinge Health (NYSE:HNGE) versus INVO Fertility (NASDAQ:IVF)

September 18 at 4:15 AM | americanbankingnews.com

INVO Fertility Announces Equity Financing and Capital Commitment

August 29, 2026 | theglobeandmail.com

INVO Fertility to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

August 28, 2026 | globenewswire.com

INVO Fertility Announces Five Poster Presentations Highlighting Platelet-Rich Plasma Research at the 2026 Midwest Reproductive Symposium International

August 20, 2026 | globenewswire.com

INVO Fertility Stock Surges Following Q2 Earnings Beat

August 17, 2026 | benzinga.com

INVO Fertility Q2 revenue rises 17% as clinic-level profitability improves

August 17, 2026 | msn.com

INVO Fertility Reports 17% Q2 Revenue Growth and $888,740 Net Income

August 17, 2026 | quiverquant.comQ

INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability

August 17, 2026 | globenewswire.com

INVO Fertility Inc

July 29, 2026 | cnn.com

INVO Fertility Stock Dividends | NASDAQ:IVF | Benzinga

July 12, 2026 | benzinga.com

What's going on with INVO Fertility stock Monday?

June 29, 2026 | msn.com

Why INVO Fertility Stock Is Surging Friday Afternoon

June 26, 2026 | benzinga.com

SHPH, ILLR, IVF: Why These Stocks Posted Double-Digit Gains After-Hours Today

June 25, 2026 | finance.yahoo.com

INVO Fertility Reports First Quarter 2026 Results Reflecting Strong Revenue Growth, Expanded Fertility Clinic Platform, and Improved Capital Structure

June 22, 2026 | globenewswire.com

INVO Fertility, Inc. Receives Nasdaq Delinquency Notice for Filing Violations

June 2, 2026 | quiverquant.comQ

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Quarterly Report on Form 10-Q

June 2, 2026 | globenewswire.com

INVO Fertility Announces Fiscal Year 2025 Financial Results

June 2, 2026 | globenewswire.com

INVO Fertility Discloses Delay In Quarterly Filing

May 20, 2026 | theglobeandmail.com

INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K

April 29, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVF, BMGL, AIDX, and GXAI Company Descriptions

20/20 Biolabs NASDAQ:AIDX

$0.47 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.46 -0.01 (-1.10%)

As of 09/18/2026 07:46 PM Eastern

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.

Basel Medical Group NASDAQ:BMGL

$4.61 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.82 +0.22 (+4.66%)

As of 05:10 AM Eastern

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.

Gaxos.ai NASDAQ:GXAI

$0.60 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.28%)

As of 04:59 AM Eastern

Gaxos.ai Inc. engages in developing artificial intelligence applications for various sectors. Its portfolio includes applications in mental and physical wellbeing, coaching, and gaming. In addition, it offers Gaxos, a gaming platform develop, design, acquire, and manage conventional games and combine these games with unconventional game mechanisms. The company was formerly known as The NFT Gaming Company, Inc. and changed its name to Gaxos.ai Inc. in January 2024. Gaxos.ai Inc. was incorporated in 2021 and is based in Roseland, New Jersey.

INVO Fertility NASDAQ:IVF

$0.97 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.94 -0.03 (-3.30%)

As of 04:40 AM Eastern

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVF, BMGL, AIDX, and GXAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVF, BMGL, AIDX, and GXAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVF, BMGL, AIDX, and GXAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVF, BMGL, AIDX, and GXAI Company Descriptions

20/20 Biolabs NASDAQ:AIDX

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

INVO Fertility NASDAQ:IVF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IVF, BMGL, AIDX, and GXAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IVF, BMGL, AIDX, and GXAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IVF, BMGL, AIDX, and GXAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVF, BMGL, AIDX, and GXAI Company Descriptions

20/20 Biolabs NASDAQ:AIDX

Basel Medical Group NASDAQ:BMGL

Gaxos.ai NASDAQ:GXAI

INVO Fertility NASDAQ:IVF

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools